The latest from across eye care — curated by B-Seen
NEWARK, N.J.—The national average for gross revenue at ECP locations increased last month, March 2026, when compared with the previous month, at a rate of 17 index points. That places gross revenue at a level 2 index points above where it was at this point in time (March) when compared with last year (2025), 16 points below the same period in 2024, 11 points above 2023, 18 points above 2022, 25 points above 2021, 81 points above 2020, during the onset of the COVID 19 pandemic, and 55 points above 2019, according to Jobson’s most recent Practice Performance Tracker.
LAKE FOREST, Calif.—STAAR Surgical Company (NASDAQ: STAA), a global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, has announced preliminary net sales for the first quarter ended April 3, 2026. Net sales for the first quarter of 2026 are expected to be in excess of $90 million, compared with net sales of $42.6 million for the first quarter of 2025, according to the announcement from the company.
RESEARCH TRIANGLE PARK, N.C.—Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced it has entered into a strategic financing agreement with Oberland Capital Management LLC that includes up to $155 million in non-dilutive funding with an upfront payment of $35 million and a $5 million equity investment. This strategic financing will accelerate the clinical development, manufacturing and potential commercialization of its broad gene therapy pipeline to maximize shareholder value, the announcement said.
PEMBROKE, N.C.—The University of North Carolina at Pembroke (UNCP) announced that it has been awarded a $4,864,368 grant from the Golden LEAF Foundation to support its new College of Optometric Medicine. UNC Pembroke said in the announcement that it will break ground on the new Clinical Sciences Building this Friday, April 10, and this grant will fund critical clinical and training lab equipment to enable hands-on learning and advanced technology-based patient care and is “helping shape the future of health care in southeastern North Carolina.”
Luminopia has a clinically meaningful benefit for children with severe amblyopia, according to a study presented at the American Association for Pediatric Ophthalmology and Strabismus meeting. Other studies found that the headset-based therapy had particular benefit for older children and that amblyopia recurred less frequently after Luminopia treatment. “We’re seeing growing evidence to support Luminopia use in a diverse group of patients across a broad spectrum of amblyopia,” Shelley Hancock, senior director of medical affairs at Luminopia, told Healio. The studies were
Drug Supply Chain Security Act compliance policy guidances establish 1-year stabilization period for implementation of electronic interoperable systems
Editor’s note: This is a developing news story. Please check back soon for updates. Oculus received FDA clearance for its Pentacam Cornea OCT system, according to a company press release. Pentacam Cornea OCT features a combination of Scheimpflug technology and high-resolution, pericentric optical coherence tomography imaging. Both measurements can be taken at the same time at the same location, according to the release. The system is compatible with existing Oculus Pentacam examination data, which the company said will simplify follow-up exams and progression analysis. “We are excited to
Johnson & Johnson will present data from two major studies supporting the performance of its recently FDA-approved Tecnis PureSee IOL at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, April 10-13 in Washington, DC. Tecnis PureSee IOL is a purely refractive Extended Depth of Focus (EDOF) IOL with improved range of vision compared to a monofocal IOL.1 “The data presented at ASCRS 2026 confirms that Tecnis PureSee IOL provides patients with high contrast sensitivity and visual acuity across distances, with low levels of visual disturbances,” said Paul Lisenby, Global Head of Research and Development, Vision, Johnson & Johnson. “This evidence underscores our commitment to advancing innovation through rigorous clinical research—extending the range of vision for our patients and reinforcing surgeon confidence.” Additional presentations will showcase positive results from the broader Tecnis family of IOLs—including evidence of their high tolerance to refractive error and range of vision. New data for Tecnis Odyssey IOL reveals high tolerance in patients with astigmatism, including high spectacle independence, and low rates of severe dysphotopsias. Additionally, new data from the Veritas Vision System showed no measurable endothelial cell count loss. Notable findings for TECNIS PureSee IOL: Results from a US prospective, randomized clinical trial involving over 200 patients across nine sites with Tecnis PureSee IOL show high-quality distance visual acuity, significantly improved intermediate vision vs monofocal control Tecnis 1-pc IOL, with some near vision gained while maintaining contrast sensitivity comparable to an aspheric monofocal IOL and low levels of visual symptoms. Three datasets will be highlighted at the meeting: Quality of Vision Clinical Outcomes for a New Extended Depth of Focus (EDOF) Intraocular Lens (IOL); Donnenfeld, MD– (Abstract) Evaluates the quality of vision of a new purely refractive extended depth of focus IOL in comparison to a standard aspheric monofocal IOL. Data shows Tecnis PureSee IOL provided: Low rates of visual disturbances Improved intermediate and near vision with higher spectacle independence compared to a monofocal IOL while maintaining contrast sensitivity and comparable distance vision acuity with pupil independent performance Depth of Focus and Visual Performance of a New Purely Refractive Extended Depth of Focus (EDOF) IOL– Daniel Chang DH, MD (Abstract) Evaluates the visual performance and patient reported outcomes of Tecnis PureSee IOL as compared to a standard aspheric monofocal IOL, showing: Strong distance-corrected intermediate vision of 20/28 (mean monocular) Some near vision gained with 1.5 lines of difference over control A broader range of clear focus, pupil independence performance and overall spectacle independence in most subjects in the Tecnis PureSee IOL group Comparison of Tolerance to Refractive Error of a New Purely Refractive Extended Depth of Focus (EDOF
Lumibird Medical announced that it has entered into discussions to acquire its long-standing distribution partner, Biz Medic Z SDN BHD, based in Kuala Lumpur, Malaysia. The proposed acquisition paves the way for the creation of Lumibird Medical Southeast Asia, a new regional hub aimed at accelerating growth. According to Lumibird, the move represents a transition from a distributor-led model to a direct subsidiary structure, underscoring the company's commitment to strengthening its presence in the Asia-Pacific region. Southeast Asia has emerged as a critical frontier for eye care, driven by a combination of high clinical demand and rapidly expanding healthcare infrastructure, the company stated. The region faces some of the highest global rates of vision impairment, particularly myopia, alongside a growing prevalence of ophthalmic diseases such as glaucoma and retinal disorders. At the same time, increasing investment in healthcare systems is creating significant opportunities for advanced diagnostic and therapeutic laser technologies. As part of this strategic realignment, Lumibird Medical will centralize its regional operations under the new Southeast Asia hub. This consolidation will involve the closure of its representative office in Thailand and its subsidiary in India, allowing the company to streamline resources and focus on a unified regional approach. Biz Medic Z SDN BHD has been a partner to Lumibird Medical since 2004, helping build the company’s footprint across Southeast Asia. “This acquisition is a pivotal step in our global strategy,” said Jean-Marc Gendre, Director of Lumibird Medical. “Southeast Asia is not just a growing market; it is the most populous region with some of the highest unmet needs in ophthalmology. By establishing this office, we are moving closer to our customers and patients, ensuring that our life-changing technologies are supported by a world-class regional service center.” The transaction is expected to be finalized in the first half of the year. The new Southeast Asia hub will oversee the distribution of Lumibird Medical’s product portfolios, including Quantel Medical, Optotek Medical, and Ellex. This integration is expected to deliver a unified brand presence while addressing the specific regulatory and clinical requirements unique to the Southeast Asian market.
Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology. This month we will focus on a revolutionary milestone in the treatment of endothelial dysfunction. Building upon the pioneering work of Shigeru Kinoshita, MD, PhD, and thanks to the innovative spirit and commitment of Aurion Biotech, corneal endothelial cell therapy has now reached the market in Japan, and phase 3 trials are soon to begin in the U.S. Minimally invasive and highly effective, easier
A 44-year-old woman presented to an outside ophthalmology clinic with significant nausea, blurry vision in the right eye and right-sided headache. She was found to have elevated IOP that did not respond to maximum medical therapy including topical IOP-lowering medications and oral acetazolamide. She was referred to the Tufts New England Eye Center glaucoma clinic due to concern for acute angle closure. She had no significant medical or surgical history. She had no known allergies, and there was no known alcohol or drug abuse history. Family history was noncontributory. On initial exam, the
The conjunctiva is the outermost ocular epithelial layer, lining the ocular surface. Trauma, insect bite allergy or autoimmune conditions can cause conjunctival necrosis. Rarely, post-surgical intervention after excess cautery or mitomycin C usage can lead to conjunctival necrosis. In this report, we see a young patient with post-phacoemulsification conjunctival necrosis and ulceration. A 33-year-old woman who had blurred vision was diagnosed with bilateral presenile cataract and underwent uneventful phacoemulsification in her left eye under local anesthesia. Her initial 1-week postoperative
Drug Supply Chain Security Act compliance policy guidances establish 1-year stabilization period for implementation of electronic interoperable systems
Hoya Vision Care has released a new “Sustainability in Action” report updating its One Vision program, the company’s long-term sustainability roadmap launched in 2023. Hoya said the updated plan includes an accelerated target to use 100 percent renewable electricity across all operations by 2030, moving up its earlier 2040 goal and aligning with the Climate Group’s RE100 initiative.
Key Takeaways FDA granted 510(k) clearance for Bausch + Lomb’s Bi-Blade+ vitrectomy cutter and Adaptive Fluidics update, expanding capabilities of the Stellaris Elite system Bi-Blade+ delivers faster cutting speeds (25,000 cpm), improved flow, and reduced vibration Adaptive Fluidics enables real-time fluid management, improving IOP stability and supporting better surgical outcomes Bausch + Lomb announced that the FDA has granted 510(k) clearance for two innovations designed to enhance vitreoretinal surgery: the Bi-Blade+ advanced dual-port vitrectomy cutter and the Adaptive Fluidics update for the Stellaris Elite Vision Enhancement System. The newly cleared technologies aim to improve surgical precision, efficiency, and IOP stability. “Retinal surgeons who are familiar with our Bi-Blade technology understand the benefits of its dual-port design, 100% open duty cycle and cutting speed of 15,000 cuts per minute,” said Wayne Caulder, vice president and general manager, North America Surgical, Bausch + Lomb. “Bi-Blade+ builds on that foundation with an increased cutting speed of 25,000 cuts per minute. When combined with Adaptive Fluidics, surgeons will experience enhanced stability, efficiency and control that can streamline procedures and support exceptional patient outcomes.” The Bi-Blade+ vitrectomy cutter introduces several performance improvements over its predecessor. It delivers a 25% increase in flow rate, enabling more efficient removal of vitreous material. Additionally, at maximum speed, the device demonstrates a 62% reduction in cutter vibration, which can improve surgical precision and provide a more stable, controlled experience for surgeons, according to Bausch + Lomb. The Adaptive Fluidics update represents an advancement in fluid management during surgery. The system automatically adjusts fluid infusion into the eye in response to real-time vacuum commands, allowing for precise and responsive control throughout the procedure. Together, Bi-Blade+ and Adaptive Fluidics work to maintain consistent IOP. Clinical findings indicate that their combined use results in a 62% reduction in average infusion pressure compared to procedures without Adaptive Fluidics. Continuous aspiration further supports stable IOP levels, helping maintain conditions closer to the physiologic range of 10–20 mmHg, even during high vacuum settings. “Bi-Blade has been an essential tool for me in a variety of surgeries, including core vitrectomies, vitreous shaving near mobile retina, removal of intraocular tissues and dissections,” said Professor Marco Mura, MD, of the University of Ferrara in Italy. “The increased cut speed that Bi-Blade+ offers, paired with the additional control of Adaptive Fluidics, promises to further promote stability and efficiency during surgery.”
Key Takeaways Oculus has launched the Pentacam Cornea OCT in the U.S., combining Scheimpflug imaging with a pericentric OCT system The technology enables more comprehensive corneal assessment, helping clinicians detect abnormalities with greater clarity The device is fully compatible with existing Pentacam data, supporting seamless follow-up and progression analysis Oculus has introduced the Pentacam Cornea OCT to the US market, unveiling a next-generation diagnostic platform that integrates Scheimpflug imaging with what the company describes as the world’s first pericentric OCT scanning system. According to Oculus, the new device delivers both Scheimpflug-based measurements and ultra high-resolution optical coherence tomography (OCT) images of the cornea in just 1 second. By capturing both data sets simultaneously at the same locations, the system enables clinicians to visualize corneal structures and detect abnormalities with greater precision and efficiency. “We are excited to introduce this advanced imaging technology to the US market, supporting cataract and refractive specialists with anterior segment imaging and corneal epithelium assessment,” said Michael Wolber, CEO of Oculus. The combined imaging approach is designed to provide a more comprehensive assessment of the cornea, potentially enhancing diagnostic accuracy and clinical decision-making in refractive and cataract care. The integration of OCT with Scheimpflug imaging allows practitioners to evaluate both surface and subsurface corneal features in a single scan. Oculus noted that the new system is fully compatible with existing Pentacam examination data across all models and software versions. This backward compatibility is expected to streamline follow-up visits and support long-term progression analysis without disrupting existing clinical workflows. The Pentacam Cornea OCT is being showcased at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, D.C., where attendees can see live demonstrations at Oculus Booth #1406. Additional information about the device is available at www.pentacam-cornea-oct.us.
Key Takeaways Aurion Biotech has begun dosing patients in its US phase 3 ASTRA trial of AURN001, a regenerative cell therapy that could become the first approved treatment of its kind for corneal endothelial disease The therapy uses cultured human corneal endothelial cells combined with a rho-kinase inhibitor, delivered via a single injection The trial is a critical step toward US regulatory approval Aurion Biotech announced that the first patients have been dosed in the US phase 3 ASTRA clinical trial evaluating AURN001, an investigational therapy for corneal edema caused by corneal endothelial dysfunction. The milestone marks a step toward what could become the first approved cell therapy in the United States for this condition, a leading cause of vision impairment globally. “Dosing the first ASTRA study participants marks an important milestone for patients, physicians, and Aurion as we work together to advance new solutions for vision loss from corneal endothelial disease,” said Edward J. Holland, MD, Chief Medical Officer at Aurion Biotech. He noted that while endothelial keratoplasty procedures have improved outcomes, challenges remain. “AURN001 represents the potential next evolution by moving from donor tissue-based graft surgery toward a cultured cell therapy designed to restore corneal clarity and expand access to care for patients worldwide.” The ASTRA study is a pivotal phase 3 trial that will enroll patients across 12 sites in the United States. Participants will receive AURN001 in combination with Y-27632, a rho-kinase inhibitor. The primary endpoint is the proportion of patients achieving a clinically meaningful improvement in vision—defined as a gain of at least 15 letters in Best Corrected Visual Acuity (BCVA)—at 6 months. Secondary measures include changes in corneal thickness and additional visual acuity improvements. AURN001 is a first-in-class combination therapy composed of cultured human corneal endothelial cells (neltependocel) and Y-27632. Delivered via a single intracameral injection, the therapy is designed to regenerate the corneal endothelium, restore clarity, and potentially reduce complications associated with traditional transplant surgery while enabling faster recovery. “This pivotal study is the foundation for our U.S. biologics license application and a critical step in our mission to address a very large global unmet patient need,” said Arnaud Lacoste, PhD, MBA, the company’s CEO and Chief Scientific Officer. “By using donor corneas to create scalable and transportable cell therapy, we are overcoming the limitations of traditional surgery.” The company pointed to prior success in Japan as a foundation for its global ambitions, with the ASTRA trial representing a key step toward expanding access to regenerative treatments for blindness worldwide. More information about the ASTRA trial is available at aurionclinicaltrials.com and on ClinicalTrials.gov under identifier NCT07368959.
ALEXANDRIA, Va.—The American Optometric Association (AOA) has announced that the first class of the AOA Center for Independent Practice’s (CIP) Independent Practice Institute (IPI) has graduated. The AOA’s CIP prepares students and optometrists for independent practice through educational opportunities and collaboration with established doctors of optometry, the AOA said. A new member-only benefit designed to prepare optometrists of all experience levels for independent practice ownership and leadership, the AOA IPI equips participants with the full spectrum of skills required to successfully launch, lead and grow an independent practice, the AOA said.
CHICAGO—Prevent Blindness has once again declared April as Women’s Eye Health and Safety Month, an annual observance aimed at providing women with resources needed to help save their vision. Women are at a higher risk for sight-threatening eye diseases, and vision can change during pregnancy and menopause, Prevent Blindness said. The nonprofit eye health organization is offering free educational resources to consumers and health care professionals, including videos, fact sheets, social media graphics, educational videos and web pages. All of these are accessible for independent eyecare providers to use within their practices.
LA JOLLA, Calif.—Topcon Healthcare, Inc., a global leader in digital health and ocular data solutions, has announced two leadership appointments designed to strengthen execution across the Americas and further align global strategy and business development across Topcon Corporation’s eyecare business. Effective April 1, 2026, Lance Patton has been promoted to president of Topcon Healthcare, Inc., taking over the role from Ali Tafreshi, who remains as CEO. In addition to his responsibilities as CEO of Topcon Healthcare, Inc., Tafreshi will assume the newly created role of chief of strategy for Topcon Corporation’s global eyecare business, the company noted. Topcon Corporation is the parent company of Topcon Healthcare.
VANCOUVER, British Columbia—Kits Eyecare Ltd. (TSX: KITS), a leading vertically integrated eyecare provider, has released preliminary unaudited results for its first quarter ended March 31, 2026. The Canadian digital eyewear retailer announced that revenue in Q1 was forecasted to be 57.4 million Canadian dollars ($41.3 million), representing a 23 percent increase over the prior-year period. Revenue from sales of glasses increased 61 percent year-over-year to approximately $10.8 million, the company reported, exceeding 6 percent of total revenue.
POMONA, Calif.—K.C. Pharmaceuticals, Inc., a manufacturer and private-label supplier of over-the-counter (OTC) eyecare products in North America, initiated a nationwide voluntary recall for more than 3 million bottles of eye drop products citing “lack of assurance of sterility,” according to the U.S. Food and Drug Administration (FDA). The FDA categorizes the recall as Class II, which is for products that may cause “temporary or medically reversible adverse health consequences,” where the probability of serious injury is remote. The recall of 3,111,072 bottles from eight product lines began on March 3, 2026, and was classified by the FDA on March 31.
ROCHESTER, N.Y.—CooperVision and the American Optometric Association (AOA) announced they have opened applications for 17 new change agent positions across 15 states as part of the continued expansion of The Myopia Collective, the organizations’ national initiative to deliver the standard of care for children with myopia. For the first time, the program will welcome student change agents from across the nation’s optometry schools, selecting one rising fourth-year leader from each of the 25 institutions to take action early and strengthen the movement’s long term impact, the announcement noted.
LONDON and SEATTLE—Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company with a focus on vision in the aging eye, has announced the appointment of Stephen S. Lane, MD, as chief medical officer (CMO), effective immediately. In this role, Dr. Lane will join the executive team and oversee the company’s clinical development strategy, medical affairs and pharmacovigilance, the company said. Dr. Lane brings significant ophthalmology leadership experience in both clinical practice and the pharmaceutical industry, most recently serving as chief medical officer and head of medical safety at Alcon, according to Tenpoint Therapeutics.
Optometrists in Kansas are now permitted to perform some laser surgeries under a bill signed by Kansas Gov. Laura Kelly on March 13. The law allows optometrists to perform laser capsulotomy and laser trabeculoplasty. Its enactment makes for “exciting times in Kansas,” Nate Lighthizer, OD, FAAO, FAAOMS, vice president of the American Academy of Optometric Medicine and Surgery, who testified in support of the bill, told Healio. The law allows optometrists to prescribe and administer pharmaceutical drugs through “all routes of administration, except intraocular injections.”
NEWARK, N.J.—The national average for gross revenue at ECP locations increased last month, March 2026, when compared with the previous month, at a rate of 17 index points. That places gross revenue at a level 2 index points above where it was at this point in time (March) when compared with last year (2025), 16 points below the same period in 2024, 11 points above 2023, 18 points above 2022, 25 points above 2021, 81 points above 2020, during the onset of the COVID 19 pandemic, and 55 points above 2019, according to Jobson’s most recent Practice Performance Tracker.
LAKE FOREST, Calif.—STAAR Surgical Company (NASDAQ: STAA), a global leader in phakic IOLs with the EVO family of Implantable Collamer Lenses (EVO ICL) for vision correction, has announced preliminary net sales for the first quarter ended April 3, 2026. Net sales for the first quarter of 2026 are expected to be in excess of $90 million, compared with net sales of $42.6 million for the first quarter of 2025, according to the announcement from the company.
RESEARCH TRIANGLE PARK, N.C.—Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced it has entered into a strategic financing agreement with Oberland Capital Management LLC that includes up to $155 million in non-dilutive funding with an upfront payment of $35 million and a $5 million equity investment. This strategic financing will accelerate the clinical development, manufacturing and potential commercialization of its broad gene therapy pipeline to maximize shareholder value, the announcement said.
PEMBROKE, N.C.—The University of North Carolina at Pembroke (UNCP) announced that it has been awarded a $4,864,368 grant from the Golden LEAF Foundation to support its new College of Optometric Medicine. UNC Pembroke said in the announcement that it will break ground on the new Clinical Sciences Building this Friday, April 10, and this grant will fund critical clinical and training lab equipment to enable hands-on learning and advanced technology-based patient care and is “helping shape the future of health care in southeastern North Carolina.”
Luminopia has a clinically meaningful benefit for children with severe amblyopia, according to a study presented at the American Association for Pediatric Ophthalmology and Strabismus meeting. Other studies found that the headset-based therapy had particular benefit for older children and that amblyopia recurred less frequently after Luminopia treatment. “We’re seeing growing evidence to support Luminopia use in a diverse group of patients across a broad spectrum of amblyopia,” Shelley Hancock, senior director of medical affairs at Luminopia, told Healio. The studies were
Drug Supply Chain Security Act compliance policy guidances establish 1-year stabilization period for implementation of electronic interoperable systems
Editor’s note: This is a developing news story. Please check back soon for updates. Oculus received FDA clearance for its Pentacam Cornea OCT system, according to a company press release. Pentacam Cornea OCT features a combination of Scheimpflug technology and high-resolution, pericentric optical coherence tomography imaging. Both measurements can be taken at the same time at the same location, according to the release. The system is compatible with existing Oculus Pentacam examination data, which the company said will simplify follow-up exams and progression analysis. “We are excited to
Johnson & Johnson will present data from two major studies supporting the performance of its recently FDA-approved Tecnis PureSee IOL at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, April 10-13 in Washington, DC. Tecnis PureSee IOL is a purely refractive Extended Depth of Focus (EDOF) IOL with improved range of vision compared to a monofocal IOL.1 “The data presented at ASCRS 2026 confirms that Tecnis PureSee IOL provides patients with high contrast sensitivity and visual acuity across distances, with low levels of visual disturbances,” said Paul Lisenby, Global Head of Research and Development, Vision, Johnson & Johnson. “This evidence underscores our commitment to advancing innovation through rigorous clinical research—extending the range of vision for our patients and reinforcing surgeon confidence.” Additional presentations will showcase positive results from the broader Tecnis family of IOLs—including evidence of their high tolerance to refractive error and range of vision. New data for Tecnis Odyssey IOL reveals high tolerance in patients with astigmatism, including high spectacle independence, and low rates of severe dysphotopsias. Additionally, new data from the Veritas Vision System showed no measurable endothelial cell count loss. Notable findings for TECNIS PureSee IOL: Results from a US prospective, randomized clinical trial involving over 200 patients across nine sites with Tecnis PureSee IOL show high-quality distance visual acuity, significantly improved intermediate vision vs monofocal control Tecnis 1-pc IOL, with some near vision gained while maintaining contrast sensitivity comparable to an aspheric monofocal IOL and low levels of visual symptoms. Three datasets will be highlighted at the meeting: Quality of Vision Clinical Outcomes for a New Extended Depth of Focus (EDOF) Intraocular Lens (IOL); Donnenfeld, MD– (Abstract) Evaluates the quality of vision of a new purely refractive extended depth of focus IOL in comparison to a standard aspheric monofocal IOL. Data shows Tecnis PureSee IOL provided: Low rates of visual disturbances Improved intermediate and near vision with higher spectacle independence compared to a monofocal IOL while maintaining contrast sensitivity and comparable distance vision acuity with pupil independent performance Depth of Focus and Visual Performance of a New Purely Refractive Extended Depth of Focus (EDOF) IOL– Daniel Chang DH, MD (Abstract) Evaluates the visual performance and patient reported outcomes of Tecnis PureSee IOL as compared to a standard aspheric monofocal IOL, showing: Strong distance-corrected intermediate vision of 20/28 (mean monocular) Some near vision gained with 1.5 lines of difference over control A broader range of clear focus, pupil independence performance and overall spectacle independence in most subjects in the Tecnis PureSee IOL group Comparison of Tolerance to Refractive Error of a New Purely Refractive Extended Depth of Focus (EDOF
Lumibird Medical announced that it has entered into discussions to acquire its long-standing distribution partner, Biz Medic Z SDN BHD, based in Kuala Lumpur, Malaysia. The proposed acquisition paves the way for the creation of Lumibird Medical Southeast Asia, a new regional hub aimed at accelerating growth. According to Lumibird, the move represents a transition from a distributor-led model to a direct subsidiary structure, underscoring the company's commitment to strengthening its presence in the Asia-Pacific region. Southeast Asia has emerged as a critical frontier for eye care, driven by a combination of high clinical demand and rapidly expanding healthcare infrastructure, the company stated. The region faces some of the highest global rates of vision impairment, particularly myopia, alongside a growing prevalence of ophthalmic diseases such as glaucoma and retinal disorders. At the same time, increasing investment in healthcare systems is creating significant opportunities for advanced diagnostic and therapeutic laser technologies. As part of this strategic realignment, Lumibird Medical will centralize its regional operations under the new Southeast Asia hub. This consolidation will involve the closure of its representative office in Thailand and its subsidiary in India, allowing the company to streamline resources and focus on a unified regional approach. Biz Medic Z SDN BHD has been a partner to Lumibird Medical since 2004, helping build the company’s footprint across Southeast Asia. “This acquisition is a pivotal step in our global strategy,” said Jean-Marc Gendre, Director of Lumibird Medical. “Southeast Asia is not just a growing market; it is the most populous region with some of the highest unmet needs in ophthalmology. By establishing this office, we are moving closer to our customers and patients, ensuring that our life-changing technologies are supported by a world-class regional service center.” The transaction is expected to be finalized in the first half of the year. The new Southeast Asia hub will oversee the distribution of Lumibird Medical’s product portfolios, including Quantel Medical, Optotek Medical, and Ellex. This integration is expected to deliver a unified brand presence while addressing the specific regulatory and clinical requirements unique to the Southeast Asian market.
Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology. This month we will focus on a revolutionary milestone in the treatment of endothelial dysfunction. Building upon the pioneering work of Shigeru Kinoshita, MD, PhD, and thanks to the innovative spirit and commitment of Aurion Biotech, corneal endothelial cell therapy has now reached the market in Japan, and phase 3 trials are soon to begin in the U.S. Minimally invasive and highly effective, easier
A 44-year-old woman presented to an outside ophthalmology clinic with significant nausea, blurry vision in the right eye and right-sided headache. She was found to have elevated IOP that did not respond to maximum medical therapy including topical IOP-lowering medications and oral acetazolamide. She was referred to the Tufts New England Eye Center glaucoma clinic due to concern for acute angle closure. She had no significant medical or surgical history. She had no known allergies, and there was no known alcohol or drug abuse history. Family history was noncontributory. On initial exam, the
The conjunctiva is the outermost ocular epithelial layer, lining the ocular surface. Trauma, insect bite allergy or autoimmune conditions can cause conjunctival necrosis. Rarely, post-surgical intervention after excess cautery or mitomycin C usage can lead to conjunctival necrosis. In this report, we see a young patient with post-phacoemulsification conjunctival necrosis and ulceration. A 33-year-old woman who had blurred vision was diagnosed with bilateral presenile cataract and underwent uneventful phacoemulsification in her left eye under local anesthesia. Her initial 1-week postoperative
Drug Supply Chain Security Act compliance policy guidances establish 1-year stabilization period for implementation of electronic interoperable systems
Hoya Vision Care has released a new “Sustainability in Action” report updating its One Vision program, the company’s long-term sustainability roadmap launched in 2023. Hoya said the updated plan includes an accelerated target to use 100 percent renewable electricity across all operations by 2030, moving up its earlier 2040 goal and aligning with the Climate Group’s RE100 initiative.
Key Takeaways FDA granted 510(k) clearance for Bausch + Lomb’s Bi-Blade+ vitrectomy cutter and Adaptive Fluidics update, expanding capabilities of the Stellaris Elite system Bi-Blade+ delivers faster cutting speeds (25,000 cpm), improved flow, and reduced vibration Adaptive Fluidics enables real-time fluid management, improving IOP stability and supporting better surgical outcomes Bausch + Lomb announced that the FDA has granted 510(k) clearance for two innovations designed to enhance vitreoretinal surgery: the Bi-Blade+ advanced dual-port vitrectomy cutter and the Adaptive Fluidics update for the Stellaris Elite Vision Enhancement System. The newly cleared technologies aim to improve surgical precision, efficiency, and IOP stability. “Retinal surgeons who are familiar with our Bi-Blade technology understand the benefits of its dual-port design, 100% open duty cycle and cutting speed of 15,000 cuts per minute,” said Wayne Caulder, vice president and general manager, North America Surgical, Bausch + Lomb. “Bi-Blade+ builds on that foundation with an increased cutting speed of 25,000 cuts per minute. When combined with Adaptive Fluidics, surgeons will experience enhanced stability, efficiency and control that can streamline procedures and support exceptional patient outcomes.” The Bi-Blade+ vitrectomy cutter introduces several performance improvements over its predecessor. It delivers a 25% increase in flow rate, enabling more efficient removal of vitreous material. Additionally, at maximum speed, the device demonstrates a 62% reduction in cutter vibration, which can improve surgical precision and provide a more stable, controlled experience for surgeons, according to Bausch + Lomb. The Adaptive Fluidics update represents an advancement in fluid management during surgery. The system automatically adjusts fluid infusion into the eye in response to real-time vacuum commands, allowing for precise and responsive control throughout the procedure. Together, Bi-Blade+ and Adaptive Fluidics work to maintain consistent IOP. Clinical findings indicate that their combined use results in a 62% reduction in average infusion pressure compared to procedures without Adaptive Fluidics. Continuous aspiration further supports stable IOP levels, helping maintain conditions closer to the physiologic range of 10–20 mmHg, even during high vacuum settings. “Bi-Blade has been an essential tool for me in a variety of surgeries, including core vitrectomies, vitreous shaving near mobile retina, removal of intraocular tissues and dissections,” said Professor Marco Mura, MD, of the University of Ferrara in Italy. “The increased cut speed that Bi-Blade+ offers, paired with the additional control of Adaptive Fluidics, promises to further promote stability and efficiency during surgery.”
Key Takeaways Oculus has launched the Pentacam Cornea OCT in the U.S., combining Scheimpflug imaging with a pericentric OCT system The technology enables more comprehensive corneal assessment, helping clinicians detect abnormalities with greater clarity The device is fully compatible with existing Pentacam data, supporting seamless follow-up and progression analysis Oculus has introduced the Pentacam Cornea OCT to the US market, unveiling a next-generation diagnostic platform that integrates Scheimpflug imaging with what the company describes as the world’s first pericentric OCT scanning system. According to Oculus, the new device delivers both Scheimpflug-based measurements and ultra high-resolution optical coherence tomography (OCT) images of the cornea in just 1 second. By capturing both data sets simultaneously at the same locations, the system enables clinicians to visualize corneal structures and detect abnormalities with greater precision and efficiency. “We are excited to introduce this advanced imaging technology to the US market, supporting cataract and refractive specialists with anterior segment imaging and corneal epithelium assessment,” said Michael Wolber, CEO of Oculus. The combined imaging approach is designed to provide a more comprehensive assessment of the cornea, potentially enhancing diagnostic accuracy and clinical decision-making in refractive and cataract care. The integration of OCT with Scheimpflug imaging allows practitioners to evaluate both surface and subsurface corneal features in a single scan. Oculus noted that the new system is fully compatible with existing Pentacam examination data across all models and software versions. This backward compatibility is expected to streamline follow-up visits and support long-term progression analysis without disrupting existing clinical workflows. The Pentacam Cornea OCT is being showcased at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, D.C., where attendees can see live demonstrations at Oculus Booth #1406. Additional information about the device is available at www.pentacam-cornea-oct.us.
Key Takeaways Aurion Biotech has begun dosing patients in its US phase 3 ASTRA trial of AURN001, a regenerative cell therapy that could become the first approved treatment of its kind for corneal endothelial disease The therapy uses cultured human corneal endothelial cells combined with a rho-kinase inhibitor, delivered via a single injection The trial is a critical step toward US regulatory approval Aurion Biotech announced that the first patients have been dosed in the US phase 3 ASTRA clinical trial evaluating AURN001, an investigational therapy for corneal edema caused by corneal endothelial dysfunction. The milestone marks a step toward what could become the first approved cell therapy in the United States for this condition, a leading cause of vision impairment globally. “Dosing the first ASTRA study participants marks an important milestone for patients, physicians, and Aurion as we work together to advance new solutions for vision loss from corneal endothelial disease,” said Edward J. Holland, MD, Chief Medical Officer at Aurion Biotech. He noted that while endothelial keratoplasty procedures have improved outcomes, challenges remain. “AURN001 represents the potential next evolution by moving from donor tissue-based graft surgery toward a cultured cell therapy designed to restore corneal clarity and expand access to care for patients worldwide.” The ASTRA study is a pivotal phase 3 trial that will enroll patients across 12 sites in the United States. Participants will receive AURN001 in combination with Y-27632, a rho-kinase inhibitor. The primary endpoint is the proportion of patients achieving a clinically meaningful improvement in vision—defined as a gain of at least 15 letters in Best Corrected Visual Acuity (BCVA)—at 6 months. Secondary measures include changes in corneal thickness and additional visual acuity improvements. AURN001 is a first-in-class combination therapy composed of cultured human corneal endothelial cells (neltependocel) and Y-27632. Delivered via a single intracameral injection, the therapy is designed to regenerate the corneal endothelium, restore clarity, and potentially reduce complications associated with traditional transplant surgery while enabling faster recovery. “This pivotal study is the foundation for our U.S. biologics license application and a critical step in our mission to address a very large global unmet patient need,” said Arnaud Lacoste, PhD, MBA, the company’s CEO and Chief Scientific Officer. “By using donor corneas to create scalable and transportable cell therapy, we are overcoming the limitations of traditional surgery.” The company pointed to prior success in Japan as a foundation for its global ambitions, with the ASTRA trial representing a key step toward expanding access to regenerative treatments for blindness worldwide. More information about the ASTRA trial is available at aurionclinicaltrials.com and on ClinicalTrials.gov under identifier NCT07368959.
ALEXANDRIA, Va.—The American Optometric Association (AOA) has announced that the first class of the AOA Center for Independent Practice’s (CIP) Independent Practice Institute (IPI) has graduated. The AOA’s CIP prepares students and optometrists for independent practice through educational opportunities and collaboration with established doctors of optometry, the AOA said. A new member-only benefit designed to prepare optometrists of all experience levels for independent practice ownership and leadership, the AOA IPI equips participants with the full spectrum of skills required to successfully launch, lead and grow an independent practice, the AOA said.
CHICAGO—Prevent Blindness has once again declared April as Women’s Eye Health and Safety Month, an annual observance aimed at providing women with resources needed to help save their vision. Women are at a higher risk for sight-threatening eye diseases, and vision can change during pregnancy and menopause, Prevent Blindness said. The nonprofit eye health organization is offering free educational resources to consumers and health care professionals, including videos, fact sheets, social media graphics, educational videos and web pages. All of these are accessible for independent eyecare providers to use within their practices.
LA JOLLA, Calif.—Topcon Healthcare, Inc., a global leader in digital health and ocular data solutions, has announced two leadership appointments designed to strengthen execution across the Americas and further align global strategy and business development across Topcon Corporation’s eyecare business. Effective April 1, 2026, Lance Patton has been promoted to president of Topcon Healthcare, Inc., taking over the role from Ali Tafreshi, who remains as CEO. In addition to his responsibilities as CEO of Topcon Healthcare, Inc., Tafreshi will assume the newly created role of chief of strategy for Topcon Corporation’s global eyecare business, the company noted. Topcon Corporation is the parent company of Topcon Healthcare.
VANCOUVER, British Columbia—Kits Eyecare Ltd. (TSX: KITS), a leading vertically integrated eyecare provider, has released preliminary unaudited results for its first quarter ended March 31, 2026. The Canadian digital eyewear retailer announced that revenue in Q1 was forecasted to be 57.4 million Canadian dollars ($41.3 million), representing a 23 percent increase over the prior-year period. Revenue from sales of glasses increased 61 percent year-over-year to approximately $10.8 million, the company reported, exceeding 6 percent of total revenue.
POMONA, Calif.—K.C. Pharmaceuticals, Inc., a manufacturer and private-label supplier of over-the-counter (OTC) eyecare products in North America, initiated a nationwide voluntary recall for more than 3 million bottles of eye drop products citing “lack of assurance of sterility,” according to the U.S. Food and Drug Administration (FDA). The FDA categorizes the recall as Class II, which is for products that may cause “temporary or medically reversible adverse health consequences,” where the probability of serious injury is remote. The recall of 3,111,072 bottles from eight product lines began on March 3, 2026, and was classified by the FDA on March 31.
ROCHESTER, N.Y.—CooperVision and the American Optometric Association (AOA) announced they have opened applications for 17 new change agent positions across 15 states as part of the continued expansion of The Myopia Collective, the organizations’ national initiative to deliver the standard of care for children with myopia. For the first time, the program will welcome student change agents from across the nation’s optometry schools, selecting one rising fourth-year leader from each of the 25 institutions to take action early and strengthen the movement’s long term impact, the announcement noted.
LONDON and SEATTLE—Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company with a focus on vision in the aging eye, has announced the appointment of Stephen S. Lane, MD, as chief medical officer (CMO), effective immediately. In this role, Dr. Lane will join the executive team and oversee the company’s clinical development strategy, medical affairs and pharmacovigilance, the company said. Dr. Lane brings significant ophthalmology leadership experience in both clinical practice and the pharmaceutical industry, most recently serving as chief medical officer and head of medical safety at Alcon, according to Tenpoint Therapeutics.
Optometrists in Kansas are now permitted to perform some laser surgeries under a bill signed by Kansas Gov. Laura Kelly on March 13. The law allows optometrists to perform laser capsulotomy and laser trabeculoplasty. Its enactment makes for “exciting times in Kansas,” Nate Lighthizer, OD, FAAO, FAAOMS, vice president of the American Academy of Optometric Medicine and Surgery, who testified in support of the bill, told Healio. The law allows optometrists to prescribe and administer pharmaceutical drugs through “all routes of administration, except intraocular injections.”
B-Seen aggregates headlines from leading eye care publications. All content belongs to its respective publishers. Want your publication featured or removed? Contact us.
